Sign in

    Alpha Tau Medical Ltd (DRTS)

    You might also like

    Business Description

    Alpha Tau Medical Ltd. (ticker: DRTS) is a clinical-stage oncology therapeutics company headquartered in Jerusalem, Israel. The company specializes in developing innovative radiation therapy solutions for solid tumors using its proprietary Alpha DaRT® technology. Currently, Alpha Tau Medical does not sell any products as it is focused on clinical trials and research for its technology.

    1. Alpha DaRT Technology - Develops localized radiation therapy for solid tumors, utilizing alpha particles to address challenges in treating refractory or unresectable localized tumors, tumors with high unmet needs, and metastatic tumors in combination with systemic therapies.
    2. Clinical Trials - Conducts trials for various cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers, as well as preclinical studies for brain and other cancers.
    3. Manufacturing Operations - Produces Thorium-228 generators at its Lawrence, MA facility and is constructing a commercial-scale manufacturing facility in Hudson, NH, USA, while planning future expansion in Jerusalem.
    4. Research and Development - Explores combination therapies and develops manufacturing infrastructure to support Alpha DaRT technology.
    5. Regulatory and Commercialization Efforts - Pursues marketing authorizations for Alpha DaRT technology in the United States and other jurisdictions, with current authorization for commercial sale only in Israel.

    Latest news

    Recent press releases and 8-K filings for DRTS.

    Alpha Tau Medical Announces Q1 2025 Results
    $DRTS
    Earnings
    New Projects/Investments
    • Alpha Tau Medical Ltd. reported its Q1 2025 results, including a net loss of $8.7 million and increased R&D and G&A expenses, reflecting ongoing investments in clinical development.
    • Interim clinical trial data showed over 90% disease control in pancreatic cancer and a 75% systemic objective response rate in head and neck cancer trials, marking significant progress in their Alpha DaRT program.
    • The company received FDA approval for key IDE studies in pancreatic cancer and recurrent glioblastoma, setting the stage for vital U.S. pilot studies.
    • Alpha Tau bolstered its capital position by completing a $36.9 million financing in April 2025 and achieving MDSAP certification for its Jerusalem facility.
    May 19, 2025, 12:00 AM
    6-K
    Alpha Tau Medical Closes $36.9M Offering and Forms Strategic Alliance
    $DRTS
    New Projects/Investments
    • Alpha Tau Medical Ltd. closed a registered direct offering, selling 14,110,121 ordinary shares at $2.612 per share and raising gross proceeds of approximately $36.9 million.
    • The deal includes a strategic marketing alliance with Oramed Pharmaceuticals, with the investor set to provide IR/PR services and receive the right to nominate two directors within three months.
    • Net proceeds will be used for general corporate purposes including research and development, manufacturing expansion, and the potential commercialization of product candidates.
    Apr 28, 2025, 12:00 AM
    6-K
    Alpha Tau Initiates FDA-Approved Glioblastoma Trial
    $DRTS
    New Projects/Investments
    Product Launch
    • FDA approval granted for an Investigational Device Exemption to initiate a pilot study using the innovative Alpha DaRT technology for patients with recurrent glioblastoma.
    • The trial will enroll up to 10 U.S. patients with tumors not suitable for surgical resection, aiming to assess the feasibility and safety of the treatment.
    • The study builds on promising pre-clinical results and follows previous recognitions such as the FDA’s Breakthrough Device Designation.
    Apr 2, 2025, 12:00 AM
    6-K
    Alpha Tau Medical Ltd. Announces Full Year 2024 Financial Results
    $DRTS
    Earnings
    New Projects/Investments
    • Financial performance: Reported a full year net loss of $31.8 million (or $0.45 per share) with a cash balance of $62.9 million, sufficient for at least two years of operations.
    • Clinical and regulatory progress: Delivered positive interim trial results in pancreatic and head & neck cancers, including a combination trial with Keytruda, and received FDA IDE approval for a U.S. pilot study.
    • Strategic updates: Announced construction milestones for its Hudson, NH production facility and board changes with the appointment of Maya Netser.
    Mar 12, 2025, 12:00 AM
    6-K